Plain-English translation of NCT06445803 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called KQ-2002 CAR-T, which uses your own immune cells that have been specially modified in the lab to fight blood cancer. The cells are designed to recognize and attack two specific targets on leukemia and lymphoma cells. Researchers will carefully monitor your safety and how well the treatment works over a two-year period, with long-term follow-up for up to 15 years.
Many patients with advanced leukemia or lymphoma don't respond well to standard chemotherapy or keep getting sick again after treatment. This medication offers a new approach that harnesses the body's immune system to target these hard-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
First, you'll have screening visits to confirm you qualify. Then, doctors will collect some of your blood cells through a procedure called leukapheresis, which takes a few hours. Next, you'll receive three days of low-dose chemotherapy to prepare your body for the new treatment. About 2–7 days later, your specially modified cells will be infused back into you. You'll stay closely monitored in the hospital and then return for regular follow-up visits over two years, with additional long-term check-ins for up to 15 years to watch for any delayed side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China